key: cord-0285467-jvb8a3ap authors: Younes, N.; Al-Sadeq, D. W.; Shurrab, F.; Zedan, H.; Abou Saleh, H.; Abo Halawa, B.; Al Hamaydeh, F.; Elsharafi, A.; Daas, H.; Thomas, S.; Aboalmaaly, S.; Al Farsi, A.; Al-Buainain, R.; Ataelmannan, S.; Paul, J.; Saadi, A.; YASSINE, H. M.; Majdalawieh, A. F.; Ismail, A.; Abu-Raddad, L. J.; Nasrallah, G. title: Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees date: 2022-01-05 journal: nan DOI: 10.1101/2022.01.04.22268754 sha: 3808fef57f8ae62573aac8b4a856e1a6fbebb316 doc_id: 285467 cord_uid: jvb8a3ap Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: To evaluate the performance of FinecareTM2019-nCoV S-RBD LFA and its fluorescent reader (FinecareTM-FIA Meter) against the following reference methods (i) The FDA-approved Genscript surrogate virus-neutralizing assay (sVNT), and (ii) three highly performing automated immunoassays: BioMerieux VIDAS, Ortho VITROS, and Mindray CL-900i. Methods: Plasma from 488 vaccinees were tested by all aforementioned assays. Fingerstick whole-blood samples from 156 vaccinees were also tested by FinecareTM. Results and conclusions: FinecareTM showed 100% specificity as none of the pre-pandemic samples tested positive. Equivalent FinecareTM results were observed among the samples taken from fingerstick or plasma (Pearson correlation r=0.9, p<0.0001), suggesting that fingerstick samples are sufficient to quantitate the S-RBD BAU/mL. A moderate correlation was observed between FinecareTM and sVNT (r=0.5, p<0.0001), indicating that FinecareTM can be used for rapid prediction of the neutralization antibody post-vaccination. FinecareTM BAU results showed strong correlation with VIDAS (r=0.6, p<0.0001), and moderate correlation with VITROS (r=0.5, p<0.0001), and CL-900 (r=0.4, p<0.0001), suggesting that FinecareTM be used as a surrogate for the advanced automated assays to measure S-RBD BAU/mL. Serological immunoassays are rapidly emerging with varying degrees of sensitivity 24 and specificity (1, 2) . These include enzyme-linked immunosorbent assays (ELISAs), 25 chemiluminescence assays (CLIA), electrofluorescent (ELFA), and lateral flow assays 26 (LFAs). Most serological assays measure the binding antibodies (BA) response against 27 specific SARS-CoV-2 antigens. Measuring binding antibodies is insufficient for assessing 28 protective immunity since these antibodies (Abs) do not play significant roles in virus 29 neutralization (3, 4). neutralizing antibodies (nAbs) are more indicative of protective 30 immunity due to their ability not only to bind S-RBD, but also to block viral entry to the host 31 cells (3, 5-8). Therefore, neutralization assays remain the gold standard for measuring the 32 nAbs titer against SARS-CoV-2 (9). Nevertheless, nAb assays require high-level biosafety 33 laboratories, highly trained personnel and often take several days to complete (9). To avoid 34 such limitations, Genscript Biotech Corporation developed a reliable surrogate virus-35 neutralizing assay (known as sVNT or cPass) to measure the nAb. The cPass Genscript assay 36 is now recommended by the World Health Organization (WHO) and also received the full 37 USA FDA approval to be used as a reference assay for quantitative measurement of the nAb 38 (10). 39 One of the major challenges for the commercially available serology assays is that 40 their binding antibody results are provided in arbitrary units per milliliters (ARU/mL). Thus, 41 the results between assays are highly variable, although they target the same SARS-CoV-2 42 antigen, usually the S-protein. To minimize the discrepancies between serological assays, the 43 WHO introduced an international standard to harmonize the antibodies immune response 44 assessment and recommended reporting the assay results for binding activity in binding 45 antibody unit per milliliter (BAU/mL) instead of arbitrary ARU/mL. (11). One of the best 46 ways to identify a reliable assay that can be used as a surrogate assay to assess the quantity of 47 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint neutralizing Abs post-vaccination is by performing correlation studies between these assays 48 and a reference neutralization assay. 49 LFAs are attractive for small or non-laboratory settings and population surveillance. 50 They are affordable and rely on easily accessible specimens such as fingerstick whole blood, 51 and provide the result within minutes. According to the literature, none of the few 52 commercially available fluorescent LFAs that provide quantitative measurement of SARS-53 CoV-2 (in BAU/mL) to the S-RBD protein was validated. The FinecareTM2019-nCoV S-54 RBD Antibody Test is a fluorescence immunoassay used along FinecareTM FIA Meters 55 (reader) (Model No.: FS-113) for quantitative detection of S-RBD BAU in human fingerstick 56 whole blood, venipuncture whole blood, and serum or plasma specimens (12). For more 57 information about the assay principle, see Figure S1 . In this study, we aimed to evaluate the 58 performance of FinecareTM2019-nCoV by comparing its results with (i) the Genescript a 59 surrogate virus-neutralizing test (sVNT), and (ii) three highly performing commercially 60 available automated anti-SARS-CoV-2 immunoassays; Mindray CL-900i® SARS-CoV-2 S-61 RBD IgG and BioMérieux VIDAS®3, which measure BAU for S-RBD (13, 14), and Ortho 62 VITROS®, which measures total BAU to the S1 spike protein subunit (13, 14). 63 Participants who received two BNT162b2 or mRNA-1273 vaccine doses were 66 eligible for inclusion. A total of 488 EDTA whole-blood samples (5.0 mL) were collected 67 between April and October 2021 from staff and students at Qatar University, the largest 68 national university in Qatar. Plasma was separated from whole venous blood and stored at -69 80 o C until performing the test. Demographic information and information on the previous 70 infection with SARS-CoV-2 were collected through a self-administered questionnaire. Out of 71 the total samples, 156 participants in the vaccinated group performed the FinecareTM test 72 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. According to the standard phlebotomy procedure, venipuncture whole blood 89 specimens were collected from each participant in EDTA tubes. Then, plasma was separated 90 from blood immediately, and the test was performed as described above in 2.2.1. 91 Samples were analyzed using three commercially available automated anti-SARS-93 CoV-2 immunoassays assays: Mindray CL-900i® SARS-CoV-2 IgG All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint targeted antigens, sample volume, result interpretation, reported sensitivity and specificity, 99 and WHO conversion factor to BAU/mL are summarized in Table 1 . 100 2.4 cPass Genscript sVNT 108 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint The significance level was indicated at 5%, and a 95% confidence interval (CI) was reported 135 for each metric. All statistical analysis was performed using GraphPad Prism software 136 (Version 8.2.1. San Diego, CA, USA). linear regression analysis showed that constructed model could strongly predict the 164 dependent variable (R 2 =0.8, p<0.0001). Most importantly, the interpretation concordance was 165 100%, demonstrating equivalency between fingerstick and venous plasma. 166 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. The tests' agreements were studied in a pairwise fashion applying inter-rater 203 agreement statistics; (Cohen's Kappa statistic, k) ( Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Despite this rapid progress in vaccines development, it is unlikely that COVID-19 218 will be eradicated in the near future. At best, COVID-19 infections can be brought under 219 control to the point where life can return to "pre-COVID" normality (21). A key part of this 220 approach will be the deployment of high throughput testing to determine who is immune and 221 the duration of immune response (21). The rapid LFA-POC antibody tests are simple, cheap, 222 and fast. They do not require qualified personnel for interpretation and could be done in non-223 laboratory settings. The usefulness of rapid tests for detection of SARS-CoV-2 Abs has been 224 questioned regarding their inferiority compared to other serology assays. This is because 225 none of the few commercially available LFAs provide quantitative measurement of SARS-226 CoV-2 (in BAU/mL) to the S-RBD. The FinecareTM2019-nCoV S-RBD Antibody Test used 227 along FinecareTM reader is the first quantitative LFA for the detection of S-RBD BAU in 228 human fingerstick whole blood, venipuncture whole blood, and serum or plasma specimens 229 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint serology assays that detect Abs against the S1 subunit or the RBD alone strongly correlate In conclusion, SARS-CoV-2 continues to spread and threatens to disrupt human activity for 277 years to come. Fortunately, we already have vaccines that effectively reduce disease and are 278 now being rolled out in many countries but countering that many countries have low vaccine 279 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint The study was reviewed and approved by the Institutional Review Board at Qatar 305 University (QU-IRB 1537-FBA/21). All analyses were conducted according to the ethical 306 standards of the Declaration of Helsinkiof the World Medical Association (WMA). 307 308 309 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268754 doi: medRxiv preprint 9. References 310 311 Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a 312 Low-Prevalence Setting 314 Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2 Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and 318 nucleocapsid with implications for COVID-19 immunity 320 Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent 321 and critical for survival The receptor binding domain of the viral spike protein is an immunodominant and highly 324 specific target of antibodies in SARS-CoV-2 patients CoV-2 in Patients With Novel Coronavirus Disease 329 Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in 330 Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent 331 Assays and Rapid Tests Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in 334 Coronavirus Disease Patients 336 Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models WHO 339 international standard for SARS-CoV-2 antibodies to determine markers of protection. The 340 Lancet Microbe WHO 342 International Standard for evaluation of the antibody response to COVID-19 vaccines: call 343 for urgent action by the scientific community. The Lancet Microbe. 344 12. Wondfo. Finecare 2019-nCoV RBD Antibody Test Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with 348 a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-349 COV-2 Can commercial automated immunoassays be utilized to predict neutralizing antibodies after 352 SARS-CoV-2 infection? A comparative study between three different assays SARS-CoV-2 355 infection serology: a useful tool to overcome lockdown? No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Correlation analysis in clinical and experimental studies A point-368 of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 Neutralization of 371 SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients 377 Evaluation of a commercially-available surrogate virus neutralization test for severe acute 378 respiratory syndrome coronavirus-2 (SARS-CoV-2) Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological 382 Assays Dual ELISA 389 using SARS-CoV-2 nucleocapsid protein produced in E. coli and CHO cells reveals epitope 390 masking by N-glycosylation